Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial

A phase III clinical trial in treatment-naïve patients with chronic hepatitis B (CHB) revealed the safety and considerable therapeutic efficacy of a vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NASVAC) at the end of treatment (EOT) and 24 weeks af...

詳細記述

書誌詳細

主要な著者:	Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Osamu Yoshida, Eduardo Penton, Guillen Nieto Gerardo, Yoichi Hiasa
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2021-11-01
シリーズ:	Pathogens
主題:	chronic hepatitis B therapeutic vaccine sustained effects nasal vaccine NASVAC HBsAg/HBcAg vaccine
オンライン･アクセス:	https://www.mdpi.com/2076-0817/10/11/1440
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!